Turning Point Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib (TPX-0005) is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and a series of ALK inhibitors. The company was incorporated in 2013 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone858-926-5251
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees50
Next Earnings Date11/5/2019 (Estimated)
OptionableNot Optionable
Turning Point Therapeutics (NASDAQ:TPTX) Frequently Asked Questions
What is Turning Point Therapeutics' stock symbol?
Turning Point Therapeutics trades on the NASDAQ under the ticker symbol "TPTX."
How were Turning Point Therapeutics' earnings last quarter?
Turning Point Therapeutics (NASDAQ:TPTX) released its earnings results on Tuesday, August, 6th. The company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.65) by $0.05. View Turning Point Therapeutics' Earnings History.
When is Turning Point Therapeutics' next earnings date?
What price target have analysts set for TPTX?
9 brokerages have issued 1 year price objectives for Turning Point Therapeutics' stock. Their predictions range from $42.00 to $70.00. On average, they anticipate Turning Point Therapeutics' stock price to reach $54.56 in the next year. This suggests a possible upside of 48.9% from the stock's current price. View Analyst Price Targets for Turning Point Therapeutics.
What is the consensus analysts' recommendation for Turning Point Therapeutics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Turning Point Therapeutics in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Turning Point Therapeutics.
Has Turning Point Therapeutics been receiving favorable news coverage?
News articles about TPTX stock have been trending somewhat positive this week, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Turning Point Therapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Turning Point Therapeutics.
Are investors shorting Turning Point Therapeutics?
Turning Point Therapeutics saw a increase in short interest in September. As of September 30th, there was short interest totalling 2,280,000 shares, an increase of 17.5% from the August 30th total of 1,940,000 shares. Based on an average trading volume of 224,000 shares, the days-to-cover ratio is presently 10.2 days. Currently, 10.6% of the company's stock are short sold. View Turning Point Therapeutics' Current Options Chain.
Who are some of Turning Point Therapeutics' key competitors?
Some companies that are related to Turning Point Therapeutics include The Medicines (MDCO), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), United Therapeutics (UTHR), Arrowhead Pharmaceuticals (ARWR), FibroGen (FGEN), Evotec (EVTCY), Allakos (ALLK), Nektar Therapeutics (NKTR), Global Blood Therapeutics (GBT), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), Mirati Therapeutics (MRTX) and Emergent Biosolutions (EBS).
What other stocks do shareholders of Turning Point Therapeutics own?
Who are Turning Point Therapeutics' key executives?
Turning Point Therapeutics' management team includes the folowing people:
- Dr. Athena Maria Countouriotis, Pres, CEO & Director (Age 47)
- Dr. Jingrong Jean Cui Ph.D., Scientific Founder, Chief Scientific Officer & Director (Age 55)
- Mr. Brian L. Baker MS, CPA, VP of Fin. & Admin. (Age 52)
- Mr. James S. Mazzola, Sr. VP of Corp. Communication & Investor Relations
- Ms. Annette C. North, Exec. VP, Gen. Counsel & Company Sec.
When did Turning Point Therapeutics IPO?
(TPTX) raised $167 million in an initial public offering (IPO) on Wednesday, April 17th 2019. The company issued 9,300,000 shares at $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities acted as the underwriters for the IPO and Canaccord Genuity was co-manager.
When did Turning Point Therapeutics' lock-up period expire?
Turning Point Therapeutics' lock-up period expired on Monday, October 14th. Turning Point Therapeutics had issued 9,250,000 shares in its public offering on April 17th. The total size of the offering was $166,500,000 based on an initial share price of $18.00. Since the end of Turning Point Therapeutics' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.
How do I buy shares of Turning Point Therapeutics?
Shares of TPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Turning Point Therapeutics' stock price today?
One share of TPTX stock can currently be purchased for approximately $36.63.
How big of a company is Turning Point Therapeutics?
What is Turning Point Therapeutics' official website?
How can I contact Turning Point Therapeutics?
Turning Point Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The company can be reached via phone at 858-926-5251 or via email at [email protected]
MarketBeat Community Rating for Turning Point Therapeutics (NASDAQ TPTX)
MarketBeat's community ratings are surveys of what our community members think about Turning Point Therapeutics and other stocks. Vote "Outperform" if you believe TPTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TPTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
